Albert Davis is a Neurology physician affiliated with Washington University in St. Louis. OpenAlex indexes 86 publications with 4,661 citations (h-index 29).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Neurology Movement Disorders, 7th Fl
Saint Louis, MO 631101032
Telephone
314-362-6908Registry record last updated 17 Apr 2025.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
88.5%Aromatic Amino Acid Decarboxylation Inhibitor40.6%Carbidopa-Levodopa80%Carbidopa-Levodopa Er21%Part D≥107 patientsAtypical Antipsychotic10.9%Clozapine40%Quetiapine Fumarate39%Nuplazid21%Part D<11 patients+ 11 more classes in this area
Cardiovascular
9.9%Beta blocker7.7%Propranolol Hcl100%Part D≥22 patientsalpha-Adrenergic Agonist1.2%Midodrine Hcl100%Part D<11 patients+ 1 more class in this area
Hormonal (systemic)
1.6%Mineralocorticoids1.6%Fludrocortisone Acetate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2017–2026 per NIH RePORTER. The latest:
- Targeting orexin signaling to prevent synucleinopathies
Washington University
FY2026$427,625R21AG103462 - Role of APOE in endosomal processing of alpha-synuclein
Washington University
FY2024$99,532RF1AG083753 - Role of APOE in endosomal processing of alpha-synuclein
Washington University
FY2023$1,658,363RF1AG083753
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference
Alzheimer s & Dementia
2024 - IGLON5 Frequency in Idiopathic REM Sleep Behavior Disorder
Neurology Neuroimmunology & Neuroinflammation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Ley, MD
Washington University in St. Louis
David Gutmann, MD
Washington University in St. Louis
Randall Bateman, MD
Washington University in St. Louis
Victoria Fraser, MD
Washington University in St. Louis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”